Protalix BioTherapeutics (NYSE:PLX – Get Free Report) and Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Valuation & Earnings
This table compares Protalix BioTherapeutics and Amylyx Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protalix BioTherapeutics | $80.62 million | 2.68 | $8.31 million | $0.23 | 11.65 |
| Amylyx Pharmaceuticals | N/A | N/A | -$144.74 million | ($1.43) | -23.63 |
Profitability
This table compares Protalix BioTherapeutics and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
| Amylyx Pharmaceuticals | N/A | -52.92% | -48.53% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Protalix BioTherapeutics and Amylyx Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Amylyx Pharmaceuticals | 1 | 0 | 7 | 2 | 3.00 |
Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 347.76%. Amylyx Pharmaceuticals has a consensus price target of $38.86, suggesting a potential upside of 14.98%. Given Protalix BioTherapeutics’ higher probable upside, equities research analysts plainly believe Protalix BioTherapeutics is more favorable than Amylyx Pharmaceuticals.
Risk & Volatility
Protalix BioTherapeutics has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
Insider and Institutional Ownership
16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Protalix BioTherapeutics beats Amylyx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
